10月1日，美国联合医疗盘中上涨6.63%，报577.84美元/股，成交额4.55亿美元，延续前一交易日强势表现。
消息面上，多重利好持续发酵。9月30日，美国特拉华州联邦法院裁定竞争对手Liquidia的Yutrepia产品侵犯了公司'327号专利，巩固了核心产品Tyvaso在肺病治疗市场的竞争壁垒。同日BTIG将公司评级从中性上调至买入，目标价定为728美元，远高于当前股价。此外，FDA已受理Tyvaso针对特发性肺纤维化的补充新药申请及新药ralinepag的肺动脉高压新药申请，两项审批预计分别于明年4月和6月完成，管线催化剂密集。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.